ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 428

Patient-Physician Discordance of Disease Activity Assessments Predicts Inadequate Treatment Response in Early Rheumatoid Arthritis

John M. Davis III1, Cynthia S. Crowson2, Tim Bongartz1, Clement J. Michet1, Eric L. Matteson1 and Sherine E. Gabriel3, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN, 3Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose

Discordance between patients’ and physicians’ global assessments of disease activity occurs in up to a third of clinical evaluations for rheumatoid arthritis (RA).  In this study, we sought to determine the association between the presence of patient-physician discordance at baseline and clinical disease activity after the 24 weeks of disease-modifying therapy.

Methods

We conducted an observational study of consecutive patients with newly diagnosed RA recruited between July 2008 and December 2010.  RA was defined by the Leiden early RA prediction rule.  The primary rheumatologist prescribed disease-modifying therapy, which did not follow any study protocol.  Standard disease activity assessments were performed by a single joint assessor, who was independent of treatment decision-making, at baseline and at 24 weeks of follow-up, including tender and swollen joint counts, patient and physician global assessments of disease activity (0 – 100 mm visual analog scales), and the C-reactive protein.  Discordance was defined by ≥25-mm difference between the patient and physician global assessments.  A higher patient-than-physician global assessment defined positive discordance, and a higher physician-than-patient global assessment defined negative discordance.  The outcome variable of interest for this analysis was the Disease Activity Score in 28 joints, 3-variable version (which excludes the patient global assessment), using the C-reactive protein (DAS28-CRP).  The association between discordance and DAS28-CRP at 24 weeks was determined using linear regression models, adjusting for multiple study covariates.

Results

A total of 66 patients were included in this study.  The mean age was 56.4 years, and 66% was female.  As initial treatment, 51% of patients received methotrexate, 25% hydroxychloroquine, and 58% prednisone.  Patient-physician discordance was present at 27% of the baseline visits, 10% with positive discordance (i.e., patient high) and 17% with negative discordance (i.e., physician high).  The presence of positive discordance was predictive of higher DAS28-CRP after 24 weeks of disease-modifying therapy (β coefficient = 1.58; p = 0.017) whereas negative discordance was not predictive (β coefficient = 0.65; p = 0.091), after adjusting for age, sex, disease duration, rheumatoid factor, anti-CCP antibodies, baseline tender joint count, baseline swollen joint count, baseline CRP, initial DMARD, prednisone use, and smoking status. 

Conclusion

In conclusion, discordance in which patient’s assessment of disease activity is higher than the physician’s assessment is predictive of significantly higher DAS28-CRP after 24-weeks of disease-modifying therapy.  Further research is necessary to explicate factors underlying patient-physician discordance and to develop strategies for managing these factors.  This work is anticipated to improve treatment outcomes for patients with RA.


Disclosure:

J. M. Davis III,
None;

C. S. Crowson,
None;

T. Bongartz,
None;

C. J. Michet,
None;

E. L. Matteson,
None;

S. E. Gabriel,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-physician-discordance-of-disease-activity-assessments-predicts-inadequate-treatment-response-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology